Darlene Dobkowski, MA

Darlene Dobkowski, Managing Editor for CURE® magazine, has been with the team since October 2020 and has covered health care in other specialties before joining MJH Life Sciences. She graduated from Emerson College with a Master’s degree in print and multimedia journalism. In her free time, she enjoys buying stuff she doesn’t need from flea markets, taking her dog everywhere and scoffing at decaf.


Opdivo-Yervoy Combo Treatment May Prolong Survival Without Disease Progression in Subgroup of Patients With Resectable Liver Cancer

April 05, 2022

“Combination therapy with (Opdivo) plus (Yervoy) warrants further studies in the preoperative setting for patients with resectable hepatocellular carcinoma, which could transform the role of immunotherapy from palliative treatment in the metastatic setting to curative treatment in localized disease,” the study authors wrote.

Imfinzi Fails to Improve Survival in Locally Advanced Cervical Cancer

March 25, 2022

AstraZeneca, the manufacturer of the drug, announced that treatment with Imfinzi plus chemoradiotherapy did not improve survival compared with standard-of-care chemoradiotherapy alone in patients with locally advanced cervical cancer.

FDA Approves Second Keytruda Indication for Subset of Advanced Endometrial Cancer

March 21, 2022

The FDA’s approval of Keytruda is indicated for patients with advanced endometrial carcinoma with specific genetic characteristics whose disease progressed after systemic therapy and are not suitable for surgery or radiation.

Cancer Advocacy Helps Ease Nerves and Uncertainty, Says One Patient

March 14, 2022

A patient’s experience with polycythemia vera — a rare blood cancer — led to her becoming an advocate for others to help ease all the nerves and uncertainty that many patients face when they hear they have cancer.

Combination Maintenance Therapy After Stem Cell Transplant May Prolong Survival in Multiple Myeloma

March 09, 2022

Maintenance therapy with Ninlaro and Revlimid in patients with recently diagnosed multiple myeloma who underwent a stem cell transplant may safely improve survival, although more research is needed especially in high-risk patients.

Cabometyx Before Surgery May Shrink Tumors With No Disease Progression in Advanced Kidney Cancer

February 22, 2022

Treatment with Cabometyx before surgery in patients with advanced renal cell carcinoma, a type of kidney cancer, may provide benefits, although further research is required before a decision is made about its role in presurgical treatment.

Quality of Life, Outcomes After Stem Cell or Bone Marrow Transplant May Be Similar Regardless of Patient’s Relation to Donor

February 15, 2022

Patients with cancer who receive bone marrow or stem cells from either a related or unrelated donor may experience similar outcomes and quality of life post transplant, which may highlight the efforts made by teams to help patients along the way.